In the US, Ramucirumab (ramucirumab systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer and Stomach Cancer.
CAS registry number (Chemical Abstracts Service)
Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist
immunoglobulin G1-kappa, anti-[Homo sapiensvascular endothelial growth factor receptor 2 (VEGFR2,KDR,kinase insert domain receptor, FLK1,CD309) extracellular domain], Homo sapiensmonoclonal antibody; gamma1 haevy chain (1-446) [Homo sapiensVH (IGHV3-21*01 (WHO)
- Ramucirumabum (Latin)
- Ramucirumab (German)
- Ramucirumab (French)
- Ramucirumab (Spanish)
- Ramucirumab (OS: USAN)
- UNII-D99YVK4LOX (IS)
Eli Lilly, Switzerland; Eli Lilly, Croatia (Hrvatska); Eli Lilly, Ireland; Eli Lilly, Poland; Eli Lilly and Company, United Kingdom; Eli Lilly and Company, United States; Lilly, Germany; Lilly, France; Lilly, Slovenia; Lilly, Slovakia
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.